Aerie Pharmaceuticals Inc.

17.29+0.0400+0.23%Vol 274.92K1Y Perf 14.73%
Apr 19th, 2021 15:06 DELAYED
BID17.28 ASK17.30
Open17.13 Previous Close17.25
Pre-Market- After-Market-
 - -%  - -
Target Price
27.50 
Analyst Rating
Strong Buy 1.38
Potential %
59.24 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
     40.56
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap811.19M 
Earnings Rating
Sell
Price Range Ratio 52W %
67.37 
Earnings Date
5th May 2021

Today's Price Range

16.9017.38

52W Range

9.0121.30

5 Year PE Ratio Range

-11.10-6.00

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-8.39%
1 Month
-14.09%
3 Months
23.66%
6 Months
48.20%
1 Year
14.73%
3 Years
-68.72%
5 Years
13.86%
10 Years
-

TickerPriceChg.Chg.%
AERI17.290.04000.23
AAPL134.560.40000.30
GOOG2 300.923.16000.14
MSFT258.95-1.7900-0.69
XOM56.34-0.3200-0.56
WFC44.170.33000.75
JNJ162.910.67000.41
FB301.75-4.4300-1.45
GE13.450.06000.45
JPM153.15-0.1500-0.10
Financial StrengthValueIndustryS&P 500US Markets
2.80
3.20
0.90
9.41
-5.70
Leverage Ratio 6.80
ProfitabilityValueIndustryS&P 500US Markets
69.50
-199.90
-159.80
-
-
RevenueValueIndustryS&P 500US Markets
62.80M
1.34
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.75-0.79-5.33
Q03 2020-0.81-0.6519.75
Q02 2020-0.79-0.83-5.06
Q01 2020-0.75-0.84-12.00
Q04 2019-0.75-0.96-28.00
Q03 2019-0.84-0.86-2.38
Q02 2019-0.87-0.808.05
Q01 2019-0.91-0.7814.29
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.69-6.15Negative
6/2021 QR-0.65-10.17Negative
12/2021 FY-2.384.42Positive
12/2022 FY-1.32-8.20Negative
Next Report Date5th May 2021
Estimated EPS Next Report-0.69
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume274.92K
Shares Outstanding46.92M
Trades Count3.33K
Dollar Volume8.62M
Avg. Volume679.62K
Avg. Weekly Volume547.52K
Avg. Monthly Volume479.54K
Avg. Quarterly Volume702.98K

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) stock closed at 17.25 per share at the end of the most recent trading day (a -3.74% change compared to the prior day closing price) with a volume of 489.74K shares and market capitalization of 811.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 365 people. Aerie Pharmaceuticals Inc. CEO is Vicente Anido.

The one-year performance of Aerie Pharmaceuticals Inc. stock is 14.73%, while year-to-date (YTD) performance is 27.68%. AERI stock has a five-year performance of 13.86%. Its 52-week range is between 9.01 and 21.3, which gives AERI stock a 52-week price range ratio of 67.37%

Aerie Pharmaceuticals Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 37.13, a price-to-sale (PS) ratio of 14.07, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.92%, a ROC of -48.92% and a ROE of -178.00%. The company’s profit margin is -%, its EBITDA margin is -159.80%, and its revenue ttm is $62.80 Million , which makes it $1.34 revenue per share.

Of the last four earnings reports from Aerie Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.69 for the next earnings report. Aerie Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Aerie Pharmaceuticals Inc. is Strong Buy (1.38), with a target price of $27.5, which is +59.24% compared to the current price. The earnings rating for Aerie Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aerie Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aerie Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.37, ATR14 : 1.24, CCI20 : -97.26, Chaikin Money Flow : -0.09, MACD : 0.46, Money Flow Index : 49.39, ROC : -3.20, RSI : 50.54, STOCH (14,3) : 28.15, STOCH RSI : 0.00, UO : 47.40, Williams %R : -71.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aerie Pharmaceuticals Inc. in the last 12-months were: Casey C. Kopczynski (Option Excercise at a value of $11 888), Casey C. Kopczynski (Sold 30 000 shares of value $390 175 ), Gerald D. Cagle (Sold 10 000 shares of value $152 700 ), Murray A. Goldberg (Option Excercise at a value of $88 200)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (76.92 %)
10 (76.92 %)
10 (76.92 %)
Moderate Buy
1 (7.69 %)
1 (7.69 %)
1 (7.69 %)
Hold
2 (15.38 %)
2 (15.38 %)
2 (15.38 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.38
Strong Buy
1.38
Strong Buy
1.38

Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.

CEO: Vicente Anido

Telephone: +1 919 237-5300

Address: 4301 Emperor Boulevard, Durham 27703, NC, US

Number of employees: 365

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

75%25%

Bearish Bullish

64%36%

Bearish Bullish

58%42%

News

Stocktwits